il33及其受体st2与变应性鼻炎发病机制的相关性探讨-correlation between il 33 and its receptor st2 and pathogenesis of allergic rhinitis.docx

下载文档 降价啦

0
0
约3.33万字
约 37页
2018-05-29 发布于上海
举报
版权申诉
保障服务

il33及其受体st2与变应性鼻炎发病机制的相关性探讨-correlation between il 33 and its receptor st2 and pathogenesis of allergic rhinitis.docx

1、本文档共37页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

il33及其受体st2与变应性鼻炎发病机制的相关性探讨-correlation between il 33 and its receptor st2 and pathogenesis of allergic rhinitis

目录第1章前言···················································································1第2章材料与方法··········································································42.1实验材料············································································42.1.1主要试剂···································································42.1.2主要仪器···································································52.1.3主要溶液配制·····························································52.1.4临床资料··································································62.1.5治疗方案···································································72.1.6标本收集与处理··························································72.2实验方法···········································································82.2.1免疫组化SP法：检测IL-33、ST2蛋白的表达82.2.2实时荧光定量PCR：检测IL-33mRNA、ST2mRNA的相对含量表达82.2.3酶联免疫吸附测定（ELISA）：检测血清中IL-33含量122.3统计学处理·········································································14第3章结果··················································································153.1免疫组化检测结果·····························································153.1.1IL-33蛋白在两组鼻粘膜中的表达：153.1.2ST2蛋白在两组鼻粘膜中的表达：153.2荧光定量PCR检测结果163.2.1总RNA完整性凝胶结果：163.2.2IL-33及ST2mRNA在AR组和正常对照组中的相对含量分析······························································································163.3ELISA检测AR患者经SIT治疗前、后血清中IL-33的表达······18第4章讨论··················································································19第5章结论··················································································225.1结论··················································································225.2展望··················································································22致谢····························································································23参考文献·······················································································24攻读学位期间的研究成果··········································